Evidence map›Paper›PMID 38440780›Full record

ArticleOsteoarthritis and cartilage open2024

Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop.

Jackie L Whittaker, Raneem Kalsoum, James Bilzon, Philip G Conaghan, Kay Crossley, George R Dodge, Alan Getgood, Xiaojuan Li, Elena Losina, Deborah J Mason and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoarthritis and cartilage open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 9 countries.

Jackie L WhittakerDepartment of Physical Therapy, University of British Columbia, Vancouver, Canada.
Raneem KalsoumDepartment of Immunology and Inflammation, Imperial College London, London, UK.
James BilzonDepartment for Health, University of Bath, Bath, UK.
Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Kay CrossleyLa Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.
George R DodgeDepartment of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alan GetgoodDivision of Orthopedic Surgery, Bone and Joint Institute, Fowler Kennedy Sport Medicine Clinic, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
Xiaojuan LiProgram of Advanced Musculoskeletal Imaging (PAMI), Cleveland Clinic, OH, USA.
Elena LosinaDepartment of Orthopedic Surgery, Brigham and Women's Hospital, Boston, USA.
Deborah J MasonBiomechanics and Bioengineering Research Centre Versus Arthritis, School of Biosciences, Cardiff University, Cardiff, UK.
Brian PietrosimoneDepartment of Exercise and Sport Science, University of North Carolina, USA.
May Arna RisbergNorwegian School Sport Sciences, Oslo, Norway.
Frank RoemerDepartment of Radiology, Universitätsklinikum Erlangen & Friedrich- Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
David FelsonSection of Rheumatology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Adam G CulvenorLa Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.
Duncan MeuffelsOrthopedic and Sport Medicine Department, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Nicole GerwinNovartis BioMedical Research, Basel, Switzerland.
Lee S SimonSDG LLC, Cambridge, MA, USA.
L Stefan LohmanderDepartment of Clinical Sciences Lund, Orthopaedics, Lund University, Lund, Sweden.
Martin EnglundDepartment of Clinical Sciences Lund, Orthopaedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden.
Fiona E WattDepartment of Immunology and Inflammation, Imperial College London, London, UK.
Arthritis UK · GBBoston University · USLa Trobe University · AULund University · SEBrigham and Women's Hospital · USCleveland Clinic · USErasmus MC · NLHammersmith Hospital · GBImperial College London · GBIo Therapeutics (United States) · USNovartis (Switzerland) · CHOslo University Hospital · NOUniversity of British Columbia · CAUniversity of Leeds · GBWestern University · CA

Funding

Medical Research Council MR/S016538/1Medical Research Council MR/S016538/2Versus Arthritis 21509
6 · The paper itself

Abstract

Objective: The global impact of osteoarthritis is growing. Currently no disease modifying osteoarthritis drugs/therapies exist, increasing the need for preventative strategies. Knee injuries have a high prevalence, distinct onset, and strong independent association with post-traumatic osteoarthritis (PTOA). Numerous groups are embarking upon research that will culminate in clinical trials to assess the effect of interventions to prevent knee PTOA despite challenges and lack of consensus about trial design in this population. Our objectives were to improve awareness of knee PTOA prevention trial design and discuss state-of-the art methods to address the unique opportunities and challenges of these studies. Design: An international interdisciplinary group developed a workshop, hosted at the 2023 Osteoarthritis Research Society International Congress. Here we summarize the workshop content and outputs, with the goal of moving the field of PTOA prevention trial design forward. Results: Workshop highlights included discussions about target population (considering risk, homogeneity, and possibility of modifying osteoarthritis outcome); target treatment (considering delivery, timing, feasibility and effectiveness); comparators (usual care, placebo), and primary symptomatic outcomes considering surrogates and the importance of knee function and symptoms other than pain to this population. Conclusions: Opportunities to test multimodal PTOA prevention interventions across preclinical models and clinical trials exist. As improving symptomatic outcomes aligns with patient and regulator priorities, co-primary symptomatic (single or aggregate/multidimensional outcome considering function and symptoms beyond pain) and structural/physiological outcomes may be appropriate for these trials. To ensure PTOA prevention trials are relevant and acceptable to all stakeholders, future research should address critical knowledge gaps and challenges.

Indexed as

KneeOsteoarthritisPost-traumatic osteoarthritisPreventionRandomised controlled trialsTrial design

Identifiers

PMID38440780
PMCPMC10910316
OpenAlexW4392094107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.